<!DOCTYPE html>

<html>
  <head>
    <title>BCNscreening</title>
    <meta charset="utf-8" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, user-scalable=no"
    />
    <link rel="stylesheet" href="assets/css/main.css" />
  </head>
  <body class="is-preload">
  
    <div id="page-wrapper">
      <!-- Wrapper -->
      <div class="wrapper">
        <div class="inner">
          <!-- Header -->
          <header id="header">
            <a href="index.html" class="logo"
            >DETECCIÓN DEL CÁNCER DE CUELLO UTERINO<br><span>M3 Pruebas para la detección primaria del cáncer de cuello uterino</span></a
            >
            <nav>
              <ul>
                <li><a href="#menu"></a></li>
              </ul>
            </nav>

          </header>

          <!-- Nav -->

          <nav id="menu">
            <h4>ÍNDICE</h4>

            <ul class="links">
              <li><a href="M31.html">&nbspUnidad 1</a></li>
              <li><a href="M32.html">&nbspUnidad 2</a></li>
              <li><a href="M33.html">&nbspUnidad 3</a></li>
            </ul>
            <h4>RECURSOS</h4>
            <ul class="links">
              <li><a href="M3summary.html">&nbspResumen</a></li>
              <li><a href="M3biblio.html">&nbspBibliografía</a></li>
              <li>
                <a href="docs/PDFsample.pdf" target="_blank"
                  >&nbspContenido en PDF</a
                >
              </li>
            </ul>
          </nav>
          <!-- Summary -->
          <section class="main">
            <header class="major">
              <h1>BIBLIOGRAFÍA</h1>
              <h4>Revisiones</h4>
            </header>
            <ul class="alt circulito">
              <li>Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020 Jun 8;123(4):510–7.</li>
              <li>Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016 Dec 1;2(1):1–20.</li>
              <li>Singer A, Khan A. Cervical cancer screening. In: Cancer Prevention and Screening. John Wiley & Sons, Ltd; 2018 [cited 2020 Oct 27]. p. 81–100.</li>
              <li>Shiraz A, Crawford R, Egawa N, Griffin H, Doorbar J. The early detection of cervical cancer. The current and changing landscape of cervical disease detection. Cytopathology. 2020 Jul;31(4):258–70.</li>
            <li>Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Prev Med. 2017 May;98:5–14. 
            </li><li>Iftner T. Are HPV DNA or HPV E6/E7 mRNA tests the better solution for Cervical Cancer Screening? HPV World [Internet]. 2018;(56). Disponible en: www.hpvworld.com
            </li><li>Cubie HA, Campbell C. Cervical cancer screening - The challenges of complete pathways of care in low-income countries: Focus on Malawi. Womens Health (Lond Engl). 2020 Dec;16:1745506520914804. 
            </li><li>Wright Jr. TC, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Practice & Research Clinical Obstetrics & Gynaecology. 2012 Apr;26(2):197–208.</li>
            </ul>
                <hr />
                <header class="major">
                  <h4>REFERENCIAS ESPECÍFICAS MENCIONADAS</h4>
                </header>
                <ol class="alt">
                <li>Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 2006;119:1095–101.</li>
                <li>Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005;97:675–83.</li>
                <li>Danckert B, Ferlay J, Engholm G, Hansen HL, Johannesen TB, Khan S, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019) [Internet]. Association of the Nordic Cancer Registries. Danish Cancer Society.; [cited 2020 Nov 19]. Disponible en: https://www-dep.iarc.fr/nordcan/english</li>
                <li>Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191–9. </li>
                <li>Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167–77.</li>
                <li>Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–32. </li>
                <li>Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017;8:CD008587. 
                </li>
                <li>Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754. 
                </li>
                <li>Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32. 
                </li>
                <li>Loonen AJM, Huijsmans CJJ, Geurts-Giele WRR, Leeijen C, van der Linden JC, van den Brule AJC. Performance analysis of high-throughput HPV testing on three automated workflows. APMIS 2020;128:497–505. 
                </li>
                <li>Davey E, Irwig L, Macaskill P, Chan SF, D’Assuncao J, Richards A, et al. Cervical cytology reading times: a comparison between ThinPrep Imager and conventional methods. Diagn Cytopathol 2007;35:550–4. 
                </li>
                <li>Mendes D, Bains I, Vanni T, Jit M. Systematic review of model-based cervical screening evaluations. BMC Cancer 2015;15:334. 
                </li>
                <li>Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr. Opin. Obstet. Gynecol. 2013;25:11–6. 
                </li>
                <li>Malagón T, Volesky KD, Bouten S, Laprise C, El-Zein M, Franco EL. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. Int. J. Cancer 2020;
                </li>
                <li>Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine 2020;22:100293. 
                </li>
                <li>Bonde JH, Sandri M-T, Gary DS, Andrews JC. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis 2020;24:1–13.</li>
                <li>Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agents Cancer 2009;4:8. 
                </li><li>Iftner T. Are HPV DNA or HPV E6/E7 mRNA assays the better solution for Cervical Cancer Screening? HPV World [Internet] 2018; Disponible en: www.hpvworld.com
                </li><li>Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 2009;124:516–20. 
                </li><li>Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, et al. VALGENT: A protocol for clinical validation of human papillomavirus assays. J. Clin. Virol. 2016;76 Suppl 1:S14–21. 
                </li>
                
                
                <li>Poljak M, Valenčak AO, Domjanič GG, Xu L, Arbyn M. Commercially available molecular tests for human papillomaviruses: a global overview. Clinical Microbiology and Infection [Internet] 2020 [cited 2020 Apr 8]; <a
                  href="http://www.sciencedirect.com/science/article/pii/S1198743X20301798"
                  class=""
                  target="_blank"
                  >here
                  <span class="icon solid fa-external-link-alt"></span
                ></a>.
                </li>

<li>Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Prev Med. 2017;98:5–14. 
                </li><li>Veijalainen O, Kares S, Kotaniemi-Talonen L, Kujala P, Vuento R, Luukkaala T, et al. Primary HPV screening for cervical cancer: results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand 2020;
                </li>
                
                <li>WHO | Public reports of WHO prequalified IVDs (HPV virological technologies) [Internet]. WHO [cited 2021 Feb 3]; <a
                  href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/public_report_hpv/en/"
                  class=""
                  target="_blank"
                  >here
                  <span class="icon solid fa-external-link-alt"></span
                ></a>.
                </li>
                <li>HC2 High-Risk HPV DNA TestTM - Package Insert [Internet]. [cited 2017 Aug 23]; <a
                  href="https://www.google.fr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiJ0-CvzO3VAhVMshQKHbdjDKcQFggoMAA&url=https%3A%2F%2Fwww.qiagen.com%2Fuy%2Fresources%2Fdownload.aspx%3Fid%3Dded1fc02-4a2e-4e6e-9c27-1e0519605b5d%26lang%3Den&usg=AFQjCNEPBV5nWJ02tn58wn0MS-ierlGF0Q"
                  class=""
                  target="_blank"
                  >here
                  <span class="icon solid fa-external-link-alt"></span
                ></a>.
                </li>
                
             <li>Kuhn L, Saidu R, Boa R, Tergas A, Moodley J, Persing D, et al. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. The Lancet Global Health 2020;8:e296–304. 
                  </li>
                </ol>
              <hr />
      <!-- Section -->
      <section class="main">

        <header class="major">
          <h2>MÓDULO 3</h2>
        </header>
        <div class="features">
          <section>
            <a href="M31.html"><span class="icon solid fa-microscope major accent4"></span></a>
            <h3><a href="M31.html" class="button">UNIDAD 1</a></h3>
            <a href="M31.html"><p>Citología</p></a>
          </section>
          <section>
            <a href="M32.html"><span class="icon solid fa-search major accent4"></span></a>
            <h3><a href="M32.html" class="button">UNIDAD 2</a></h3>
            <a href="M32.html"><p>Pruebas de VPH</p></a>
          </section>
          <section>
            <a href="M33.html"><span class="icon solid fa-user-md major accent4"></span></a>
            <h3><a href="M33.html" class="button">UNIDAD 3</a></h3>
            <a href="M33.html"><p>Pruebas de detección primarias</p></a>
          </section>
        </div>
        <hr />

        <header class="major">
          <h2>RECURSOS</h2>
        </header>
        <div class="features">
          <section>
            <a href="M3summary.html"><span class="icon solid fa-star major accent4"></span></a>
            <h3><a href="M3summary.html" class="button">Resumen</a></h3>
          </section>
          <section>
            <a href="M3biblio.html"><span class="icon solid fa-book major accent4"></span></a>
            <h3><a href="M3biblio.html" class="button">Bibliografía</a></h3>
          </section>
          <section>
            <a  href="docs/PDFsample.pdf" target="_blank"><span class="icon solid fa-file major accent4"></span></a>
            <h3><a href="docs/PDFsample.pdf" target="_blank" class="button">PDF</a></h3>
          </section>
        </div>
      </section>
    </div>
  </div>

   <!-- Wrapper -->
   <div class="wrapper">
    <div class="inner">
      <!-- Footer -->
      <footer id="footer">
        <div class="image">
          <a href="https://www.e-oncologia.org/" target="_blank"><img src="images/logos.png" alt="" data-position="" /></a>
        </div>
      </footer>
    </div>
  </div>
</div>

<!-- Scripts -->
<script src="assets/js/jquery.min.js"></script>
<script src="assets/js/browser.min.js"></script>
<script src="assets/js/breakpoints.min.js"></script>
<script src="assets/js/util.js"></script>
<script src="assets/js/main.js"></script>
</body>
</html>